RecruitingNot ApplicableNCT01451502

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units


Sponsor

Masonic Cancer Center, University of Minnesota

Enrollment

250 participants

Start Date

Oct 20, 2011

Study Type

INTERVENTIONAL

Conditions

Summary

For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic reconstitution or other form of cellular therapy, it is critical that the investigators have access to unlicensed UCB units.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Umbilical Cord Blood (UCB) for people with hematopoietic malignancy and lymphatic diseases. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALUmbilical Cord Blood (UCB)

Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.


Locations(1)

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01451502


Related Trials